R. A. V. van Waterschoot

发表

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Ji-Ying Song, Jos H Beijnen, H. Rosing, 2007, The Journal of clinical investigation.

Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam

J. Beijnen, A. V. van Herwaarden, A. Schinkel, 2009, Drug Metabolism and Disposition.

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.

A. Schinkel, H. Gutmann, C. Zimmermann, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes

J. Goldstein, J. Beijnen, A. V. van Herwaarden, 2008, Molecular Pharmacology.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir

J. Beijnen, A. Schinkel, E. Wagenaar, 2010, British journal of pharmacology.

Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.

H. Rosing, J. Beijnen, A. V. van Herwaarden, 2009, Cancer research.

Topological role of cytochrome P450 2D6 active site residues.

Chris de Graaf, Nico P E Vermeulen, N. Vermeulen, 2006, Archives of biochemistry and biophysics.

P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine

C. Damen, J. Beijnen, A. Schinkel, 2012, Molecular Pharmacology.

Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel

H. Rosing, J. Beijnen, A. Schinkel, 2010, International journal of cancer.

ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity

H. Rosing, J. Beijnen, A. Schinkel, 2009, Clinical Cancer Research.

How important is intestinal cytochrome P450 3A metabolism?

A. V. van Herwaarden, A. Schinkel, R. A. V. van Waterschoot, 2009, Trends in pharmacological sciences.

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2010, Molecular Cancer Therapeutics.

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jos H. Beijnen, Alfred H. Schinkel, H. Rosing, 2009, Clinical Cancer Research.

A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice

A. Schinkel, R. A. V. van Waterschoot, 2011, Pharmacological Reviews.

P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2007, Antimicrobial Agents and Chemotherapy.

Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins

X. Chu, R. Evers, M. Mezler, 2014, Drug Metabolism and Disposition.

Importance of target-mediated drug disposition for small molecules.

Malcolm Rowland, Andrés Olivares-Morales, Thierry Lavé, 2018, Drug discovery today.

An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

J. Beijnen, A. Huitema, A. Schinkel, 2011, Journal of pharmaceutical sciences.

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

H. Rosing, J. Beijnen, M. Hillebrand, 2009, Clinical Cancer Research.